NCT05922761View on ClinicalTrials.gov

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Bronchiolitis Obliterans SyndromeBronchiolitis ObliteransLung DiseasesChronic Graft Versus Host Disease
Interventions
DRUG

Belumosudil

Kinase inhibitor, tablet taken orally

DRUG

Fluticasone

Via inhalation by metered-dose inhaler.

DRUG

Azithromycin

Semi-synthetic macrolide antibiotic, taken orally

DRUG

Prednisone

Corticosteroid, taken orally

DRUG

Montelukast

Leukotriene Receptor Antagonist, taken orally

Trial Locations (5)

48109

RECRUITING

University of Michigan, Ann Arbor

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02115

RECRUITING

Dana-Farber Cancer Institute, Boston

02215

NOT_YET_RECRUITING

Boston Children's Hospital, Boston

NOT_YET_RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Dana-Farber Cancer Institute

OTHER